L. C. Scott

A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma

L. C. Scott, James C. Yao, A.B. Benson et al. · Cancer Chemotherapy and Pharmacology · 2008 · 79 citations · Full text

Surgical Oncology, Oncology, Esophageal Cancer +11

Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response

L. C. Scott, T.R. Jeffry Evans, J Cassidy et al. · British Journal of Cancer · 2009 · 57 citations · Full text

Nonfatal Occupational Injury Among California Farm Operators

Stephen A. McCurdy, Jeffrey A. Farrar, James J. Beaumont et al. · Journal of Agricultural Safety and Health · 2004 · 28 citations

Occupational Health And Safety, Farm Operators, Fwr Injury +15

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours

L. C. Scott, Otto Soepenberg, Jaap Verweij et al. · Annals of Oncology · 2007 · 22 citations · Full text

Oncology, Multicentre Phase, Pharmacology +8

Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: Preliminary results of a single-agent phase 2 study

L. C. Scott, T.R. Jeffry Evans, J. C. Yao et al. · Journal of Clinical Oncology · 2004 · 10 citations

Single-agent Phase 2, Gastrointestinal Oncology, Medicine +15